NCT06599931 Cerebello-motor Neuromodulation After Stroke. CERSTIM.
| NCT ID | NCT06599931 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2024-12-13 |
| Primary Completion | 2027-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2024-12-13 with a primary completion date of 2027-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The CERSTIM study is a physiopatholgical study investigating transcranial alternating current stimulation in stroke patients in the cerebello-motor loop. The design is a cross over design testing two frequencies in the gamma band and one placebo. We will use behavioural data, functional MRI, and Electroencephalography to disentangle the effect of tACS and its frequency. Healthy participants will be also recruited.
Eligibility Criteria
PATIENTS Inclusion Criteria: * Male or female aged 18 years or older on the day of inclusion. * Affiliated with a social security system, Universal Health Coverage (CMU), or any equivalent scheme. * Ischemic stroke or intraparenchymal hematoma that occurred more than 6 months ago, with no upper time limit. * Motor deficit of the upper limb confirmed by the ARAT scale, with the ability to grip and press on a tablet. * stroke lesion not affecting the motor cortex in the hand knob area. Exclusion Criteria: \-- Pregnant and breastfeeding women * Total paralysis of the affected hand * Conditions that are life-threatening or could compromise follow-up during the study period * Contraindications to MRI and tACS (ferromagnetic surgical clips, ocular implants, intraocular or nervous system metallic foreign bodies, implants or metallic objects likely to concentrate the radiofrequency field, cochlear implants, brain or cardiac stimulators, presence of a craniotomy scar) * Participation in another biomedical study focused on motor or overall recovery during the same period, or current exclusion period from another biomedical study HEALTHY Inclusion Criteria: * Male or female aged 18 years or older on the day of inclusion. * Affiliated with a social security system, Universal Health Coverage (CMU), or any equivalent scheme. Non inclusion criteria \-- Pregnant and breastfeeding women * Conditions that are life-threatening or could compromise follow-up during the study period * Contraindications to MRI and tACS (ferromagnetic surgical clips, ocular implants, intraocular or nervous system metallic foreign bodies, implants or metallic objects likely to concentrate the radiofrequency field, cochlear implants, brain or cardiac stimulators, presence of a craniotomy scar) * Participation in another biomedical study during the same period, or current exclusion period from another biomedical study
Contact & Investigator
Charlotte ROSSO, MD PHD
PRINCIPAL INVESTIGATOR
Institut National de la Santé Et de la Recherche Médicale, France
Frequently Asked Questions
Who can join the NCT06599931 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06599931 currently recruiting?
Yes, NCT06599931 is actively recruiting participants. Contact the research team at charlotte.rosso@aphp.fr for enrollment information.
Where is the NCT06599931 trial being conducted?
This trial is being conducted at Paris, France, Toulouse, France.
Who is sponsoring the NCT06599931 clinical trial?
NCT06599931 is sponsored by Institut National de la Santé Et de la Recherche Médicale, France. The principal investigator is Charlotte ROSSO, MD PHD at Institut National de la Santé Et de la Recherche Médicale, France. The trial plans to enroll 45 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.